How the Trust is performing
The Trust collects data each month to monitor how we are performing in key areas. See below for our most recently available figures. Further information can be found in the monthly Trust board performance report.
| National standard | April 2023 | May 2023 | June 2023 | July 2023 | Aug 2023 | Sept 2023 |
| A&E: Trust overall | 68.7% | 68.1% | 69.7% | 69.7% | 68.2% | 63.5% |
| A&E: UHL | 74% | 72% | 73.75% | 76.26% | 73.9% | 68.6% |
| A&E: QEH | 64.3% | 64.9% | 66.3% | 64% | 63.3% | 59% |
| 18-week referral | 58% | 58.8% | 59.7% | 58.4% | 56% | 57.2% |
| Cancer two-week wait | 82% | 87.3% | 86.2% | 80.2% | 78.7% | |
| Cancer 62-day wait | 65.9% | 67.4% | 60.6.3% | 64% | 65% | |
| Cases of MRSA | 0 | 0 | 0 | 0 | 1 | 0 |
| Cases of C difficile | 9 | 2 | 3 | 6 | 6 | 9 |
The standards explained
A&E four-hour wait The national standard is that 95 per cent of all patients attending A&E should be treated, admitted or discharged within four hours.
18-week referral to treatment 92% of patients waiting to start elective treatment should have waited less than 18 weeks.
Cancer two-week wait 93% of urgent cancer outpatient referrals should be seen within 14 days.
Cancer 62-day standard 85% of patients should begin treatment within 62 days of being referred by their GP.
MRSA The Trust has a national target of no MRSA blood stream infections.
C. difficile the target set for our Trust was no more than 37 cases for 2022/23. For 2023/24 our target has been set at no more than 33 hospital attributable cases.